Patients with difficult-to-treat AD often experience concomitant, multiple contact allergies, which may be why their AD actually becomes a difficult-to-treat disease.
In patients with atopic dermatitis and birch pollen allergy, consumption of birch pollen-related foods is associated with allergic reactions and deterioration of AD.
Continuous treatment with emollient maximizes clinical benefit and should be considered as a first line-treatment for pediatric AD.
A recent study showed that the administration of dupilumab was associated with comparable/significant improvement in signs and symptoms of atopic dermatitis in patients with or without comorbid asthma.
The proportion of participants in the treatment groups who achieved EASI-50 was statistically significant compared with placebo as early as 4 weeks after beginning treatment.
The efficacy and generally safe profile of upadacitinib supports advancing to a phase 3 trial.
Data from a preliminary placebo-controlled trial on ASN002 were presented at the 2018 American Academy of Dermatology Annual Meeting.
The safety and efficacy of PF-04965842 was evaluated in 375 individuals in a phase 3, randomized, double-blind, placebo-controlled trial.
Despite not reaching significance in the total population, the progressive clinical improvements seen in patients with severe AD suggest a therapeutic advantage.
Twice-daily use of topical corticosteroids in all treatment arms, both prior to and during the study, impaired participants’ ability to fully assess the efficacy of lebrikizumab.
